GlassScriptPhysician profile
Deepika Kumaresan
NPI 1710373592
$1,708.85
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $671 · 2021: $513 · 2022: $59.97 · 2023: $18.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $393.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $224.13 | 2019-2020 | |
| Pfizer INC. | $137.28 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $113.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.29 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.31 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $78.77 | 2019-2021 | |
| Abbvie INC. | $61.36 | 2021-2023 | |
| Lilly USA, LLC | $53.43 | 2020-2021 | |
| Allergan, INC. | $44.96 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $43.23 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.87 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.86 | 2019-2021 | |
| Daiichi Sankyo INC. | $37.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $37.49 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.99 | 2020-2021 | |
| Vbi Vaccine (Delaware) INC. | $28.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.23 | 2019-2020 | |
| Astellas Pharma US INC | $24.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.73 | 2019-2020 | |
| Vivus LLC | $17.01 | 2021 | |
| Circassia INC. | $16.75 | 2019 | |
| Amgen INC. | $16.72 | 2019 | |
| Shire North American Group INC | $13.57 | 2019 | |
| Alnylam Pharmaceuticals INC. | $12.78 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Kumaresan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.